New York University and Leidos Inc. | Date: 2016-03-14
Mixed-phase TiO_(2 )nanofibers prepared via a sol-gel technique followed by electrospinning and calcination are provided as photocatalysts. The calcination temperature is adjusted to control the rutile phase fraction in TiO_(2 )nanofibers relative to the anatase phase. Post-calcined TiO_(2 )nanofibers composed of 38 wt % rutile and 62 wt % anatase exhibited the highest initial rate constant of UV photocatalysis. This can be attributed to the combined influences of the fibers specific surface areas and their phase compositions.
Leidos Inc. | Date: 2016-11-16
A Volatile Organic Compound (VOC) mitigation system employs a combination of technologies coupling VOC laden exhaust with a reciprocating engine and generator system (Combined Heat & Power (CHP) System) with heat recovery to destroy the VOC emissions and generate electric power and useful thermal energy.
Leidos Inc. | Date: 2016-06-24
The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.
Leidos Inc. | Date: 2016-11-10
Systems and methods are described herein for a self-referencing interferometer. The interferometer can comprise an improved spatial phase shifter that reduces the number of components, size and complexity of the spatial phase shifter and maintains a common path for a combined reference beam and signal beam. The self-referencing interferometer further comprises a single mode fiber shunt for filtering the reference beam and further reducing the size of the interferometer. The angle of the reference beam can be tilted before being recombined with the single beam which further simplifies the spatial phase shifting component of the interferometer.
Leidos Inc. | Date: 2016-11-21
A processing platform integrates ETL (extract, transform, and load), real time stream processing, and big data data stores into a high performance analytic system that runs in a public or private cloud. The platform performs real time pre-storage enrichment of data records to form a single comprehensive record usable for analytics, searching and alerting. The platform further supports sharing of components and plug-ins and performs automatic scaling of resources based on real time resource monitoring and analysis.
Leidos Inc. | Date: 2017-01-18
A system and associated method for isolating intended radiation signals for determining target characteristics includes multiple detectors for detecting radiation signals having varying energies, delay modules for delaying the detected radiation signals and a discriminator associated with the multiple detectors for determining if detected radiation signals include unintended radiation signals, e.g., x-rays, and provided blanking signals to a switch in order to effectively remove the unintended radiation signals from the data that is presented to the processor for determining target characteristics.
Leidos Inc. | Date: 2016-11-21
A process, including a mobile application, for tracking the drayage driver and vehicle movement and reporting where the driver is and how much time he has been at a location, as well as details about the driver and cargo is described. This process can correlate driver and vehicle identification and allow for the transfer of bill of lading or hazardous material restrictions. Data captured is easily be made available in advance to the port terminals (which must have container ready for pick up); available for the shipping company (which can see cargo en-routeregardless of which company the driver works for); and available for the destination warehouse (which must receive and process the shipment). The association of cargo owners, shippers, terminal yards, drayage companies, drivers, and drayage job assignments can further be linked.
Leidos Inc. | Date: 2017-07-19
Aspects of the disclosure provide a system for disease detection. The system includes an interface circuit, a memory circuit, and a disease detection circuitry. The interface circuit is configured to receive data events associated with a patient sampled at different time for disease detection. The memory circuit is configured to store configurations of a model for detecting a disease. The model is generated using machine learning technique based on time- series data events from patients that are diagnosed with/without the disease. The disease detection circuitry is configured to apply the model to the data events to detect an occurrence of the disease.
Decoste J.B.,Leidos Inc. |
Peterson G.W.,U.S. Army
Chemical Reviews | Year: 2014
The shortcoming of pure activated carbons is that chemicals with weak intermolecular forces typically have weak physical interactions with the carbon surface and therefore require chemical reactivity for removal. Thus, early gas masks were large, bulky, and burdensome to ensure proper protection for the user. Over the past century, the gas mask has changed substantially many times focused on the purported threat of the day. To properly afford broad spectrum protection, activated carbons must be impregnated with a variety of compounds capable of both acidic and basic chemistries. Due to the proximity of complementary functionalities within the pores of carbons, these chemical groups will inherently interact with one another over time, reducing the efficacy of the material. Instead, covalently anchoring functional groups to the substrate may be advantageous, a property that can be imparted through crystal design of materials, such as metal-organic frameworks (MOF).
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INFRAIA-1-2014-2015 | Award Amount: 5.63M | Year: 2015
In order to accelerate the development of the nanomedicine business in Europe, EU-NCL interconnects 8 European and 1 American key reference facilities with a proven expertise in physical, chemical, in vitro and in vivo biological characterisation of nanoparticles for medical applications. The objective is to reach a level of international excellence in nanomedicine characterization for all medical indication, and make it accessible to all organisations developing candidate nanomedicines prior to their submission to the regulatory agencies in order to get the approval for clinical trials and later the marketing authorization. EU-NCL is partnered with the sole international reference facility namely the Nanotechnology Characterisation Lab of the USA to get a faster international harmonization of analytical protocols. EU-NCL is closely connected to national medicine agencies and to the European Medicine Agency in order to permanently adapt its analytical services to the need and requests of the regulators. EU-NCL is designed, organized and operated according to the highest EU regulatory and quality standards in order to provide a full analytical cascade of 42 assays. Within EU-NCL, 6 analytical facilities will offer a Trans National Access to their existing analytical services but they will also develop new or improved analytical assays under the Joint Research Activities in order to keep EU-NCL at the cutting edge of the nanomedicine characterisation. A complementary set of networking activities will make EU-NCL able to deliver to the European academic or industrial scientists the best analytical services they dramatically require for accelerating the industrial development of their candidate nanomedicines. An exploitation and business plan will be proposed at the end of the project in order to submit a sustainable development plan beyond the initial period of 4 years.